

Neurotrophic factors in systemic lupus erythematosus: markers of disease activity

Sirs,
Brain-derived neurotrophic factor (BDNF), neurotrophic factor-3 (NT-3), neurotrophic factor-4 (NT-4), nerve growth factor (NGF) and glial cell line-derived neurotrophic factor (GDNF) are neurotrophic factors responsible for the growth, development and survival of neurons, being implicated in the pathophysiology of neuropsychiatric disorders (1). Neurotrophic factors also take part in the modulation of immune system functioning (2).

A few studies have evaluated neurotrophic factors in SLE with contradicting results (3, 4). In the current study, our main objective was to investigate whether plasma levels of BDNF, NT-3, NT-4, NGF and GDNF in patients with SLE differed from healthy controls. We also evaluated whether neurotrophic factors were associated with SLE-related parameters and depressive symptoms in patients with SLE.

Thirty-four patients with SLE followed at the Outpatient Rheumatology Clinic, Hospital das Clínicas, Federal University of Minas Gerais (UFMG) were enrolled and compared to 34 age- and sex-matched healthy individuals with no known rheumatic diseases (control group). Inclusion criteria were: age from 18 to 50 years old and diagnosis of SLE according to the American College of Rheumatology revised criteria (ACR/1997) (5). Patients presenting with acute clinical conditions and/or neuropsychiatric diseases (ACR/1999) that compromised psychopathological evaluation were excluded from the study. The study was approved by the Research Ethics Committee of UFMG. SLE activity was evaluated by the modified SLE Disease Activity Index (SLEDAI-2000). Those with an index ≥ 4 were considered active (6). Depressive symptoms were assessed with the Beck Depression Inventory (BDI). Patients with a score ≥ 21 were considered as presenting clinically meaningful depression (7). Plasma levels of neurotrophic factors were determined through enzyme-

Table I. Demographic, clinical and laboratory characteristics of patients with SLE and individuals from the control group.

Characteristics	Patients with SLE (n=34)	Control Group (n=34)	p-value
Females*	32 (94.1)	32 (94.1)	1.00
Males*	2 (5.9)	2 (5.9)	1.00
Age (anos)**	33±7	33.85±10.9	0.70
GDNF (pg/ml) [§]	51.6 (22-79)	71.5 (39.8-156.8)	0.031 [§]
NGF (pg/ml) [§]	36.8 (10.2-56.3)	66.3 (49.9-136.3)	<0.001 [§]
NT-3 (pg/ml) [§]	35.6 (7.2-107.1)	43.8 (27.2-106.3)	0.185 [§]
NT-4 (pg/ml) [§]	14.5 (7.4-32.2)	27.9 (18.8-58.5)	0.002 [§]
BDNF (pg/ml) [§]	4804 (4346-6099)	7973 (5557-9785)	<0.001 [§]
BDI (score) [#]	10 (4.8-22.3)	3.5 (1-7.3)	0.001 [§]
Mucocutaneous disorders*	6 (17.6)		
Arthritis*	4 (11.7)		
Nephritis*	6 (17.64)		
Aseptic meningitis (ACR) *	1 (2.9)		
Haematological disorders*	18 (52.4)		
Lymphopenia*	12 (35.3)		
Low C3/C4*	16 (47.1)		
Positive double strand antiDNA*	10 (30.3)		
SLEDAI-2K [#]	2 (0-26)		
Current steroid use*	28 (82.4)		
Current steroid dose (mg)**	11.4 (13)		
Cumulative steroid dose(mg)**	2016 (2140)		
Antimalarial use*	29 (85.3)		
Current immunosuppressants use*	20 (58.4)		
azathioprine*	10 (29.4)		
cyclophosphamide*	5 (14.7)		
methotrexate*	3 (8.8)		
cyclosporine*	2 (5.9)		
Thalidomide use*	1 (3.4)		
Antidepressants use*	11 (32.4)		

SLE: systemic lupus erythematosus; GDNF: glial cell line-derived neurotrophic factor; NGF: nerve growth factor; NT-3: neurotrophic factor -3; NT-4: neurotrophic factor -4; BDNF: brain-derived neurotrophic factor; SLEDAI: Systemic Lupus Erythematosus Disease Activity Index; BDI: Beck Depression Inventory; ACR: American College of Rheumatology.

*n (%), **Mean (standard deviation), [§]Median (interquartile range), [#]Median (minimum and maximum variation), [§]Mann-Whitney test.

linked immunosorbent assay (DuoSet, R&D Systems, Minneapolis, USA). Plasma levels of GDNF, NGF, NT-4 and BDNF were lower in SLE patients than in controls (Table I). When compared with controls, SLE patients had higher BDI scores. Ten SLE patients (29.4%) had depression. There was a negative correlation between GDNF and SLEDAI ($r=-0.350$; $p=0.042$). Patients with reduced levels of complement and positive anti-dsDNA had lower levels of GDNF and NGF when compared to those without laboratory abnormalities (Table II). Plasma levels of GDNF were

lower in patients with disease activity when compared to those with inactive disease [36.4 (16.9–56.46) vs. 55.4 (24.9–198.4), $p=0.043$]. Plasma levels of GDNF positively correlated with BDI ($r=0.353$; $p=0.041$). A previous study reported higher levels of neurotrophic factors in patients with SLE compared with controls (3). However, Tamashiro *et al.* (4) found that only SLE patients with an inactive disease had higher levels of BDNF when compared to controls. In line with our results, patients with active SLE had lower levels of BDNF when compared with patients with inactive

Table II. Plasma levels of neurotrophic factors in patients with SLE with and without laboratory abnormalities (n=34).

Neurotrophic factor (pg/ml)	Reduced C3			Reduced C4			Anti-dsDNA antibody		
	yes	no	p	yes	no	p	yes	no	p
GDNF*	30.7 (20.6-70.2)	54.5 (24.3-85.1)	0.395	22.3 (16.3-50.2)	56.2 (39.9-85.1)	0.018	28.6 (16.3-46.3)	56.5 (24.9-86.4)	0.018 [§]
NGF*	8.5 (0-36.7)	46.6 (23.2-60.3)	0.011	12.6 (0-38.3)	46.6 (30.9-60.3)	0.016	7.8 (0-34.7)	44.7 (25.4-60.7)	0.005 [§]
BDNF*	4476.9 (3967.5-5536.6)	4990.8 (4407.1-6234.1)	0.121	4895.7 (3967.5-6506)	4803.7 (4407.1-5562.4)	0.649	5831.6 (4528.4-7058.5)	4763 (4353.9-5591.5)	0.170 [§]

SLE: systemic lupus erythematosus; C3/C4: complement; GDNF: glial cell line-derived neurotrophic factor; NGF: nerve growth factor; BDNF: brain-derived neurotrophic factor. *Median (interquartile range), [§]Mann-Whitney test.

Letters to the Editors

disease (4). Zheng *et al.* (8) also showed that BDNF levels decreased with increasing activity of SLE.

Levels of GDNF correlated with disease activity, with lower levels indicating more severe disease. Accordingly, lower plasma levels of GDNF, NGF and BDNF were associated with laboratory changes, *i.e.* reduced levels of complement C3 and C4 and positive anti-dsDNA antibody. Tamashiro *et al.* (4) found similar results with BDNF in SLE: lower plasma levels of BDNF correlated with higher SLEDAI scores.

Increased synthesis of neurotrophic factors seems to occur during inflammatory responses (2). Nevertheless, in conditions with chronic inflammatory responses like SLE (9), there may be an exhaustion of the production of neurotrophic factors during the disease activity, which would explain decreased levels of GDNF, NGF and BDNF in patients with an increased activity of the disease.

Patients with SLE and more depressive symptoms had higher levels of GDNF. In depression, there is large variation of GDNF levels among different studies (10). As GDNF and other neurotrophic factors have been implicated in the pathophysiology of mood disorders, comorbidity with psychiatric conditions is a potential confounding factor to be considered in future studies.

A.F.M.P. DIAS, MD¹
C.C.D. LANNA, MD, PhD²
A.L. TEIXEIRA, MD, PhD³
G.A. FERREIRA, MD, PhD²

¹Rheumatology Service, Hospital Santa Casa BH, Belo Horizonte, Brazil;

²Department of Locomotor System, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil;

³Department of Psychiatry and Behavioral Sciences, The University of Texas Health Science Center, Houston, USA; Instituto de Ensino e Pesquisa, Santa Casa BH, Belo Horizonte, Brazil.

Please address correspondence to:
Gilda Aparecida Ferreira,
Department of Locomotor System,
Medical School,
Universidade Federal de Minas Gerais,
Av. Alfredo Balena 190,
CEP 30130-100, Belo Horizonte,
Minas Gerais, Brazil.
E-mail: gildajferreira9@gmail.com

Competing interests: none declared.

© Copyright CLINICAL AND
EXPERIMENTAL RHEUMATOLOGY 2021.

References

1. SOFRONIEW MV, COOPER JD, SVENDSEN CN *et al.*: Atrophy but not death of adult septal cholinergic neurons after ablation of target capacity to produce mRNAs for NGF, BDNF, and NT3. *J Neurosci* 1993; 13: 5263-76.
2. RAYCHAUDHURI SP, RAYCHAUDHURI SK, ATKURI KR, HERZENBERG LA, HERZENBERG LA: Nerve growth factor: A key local regulator in the

pathogenesis of inflammatory arthritis. *Arthritis Rheum* 2011; 63: 3243-52.

3. BRACCI-LAUDIERO L, ALOE L, LEVI-MONTALCINI R *et al.*: Increased levels of NGF in sera of systemic lupus erythematosus patients. *Neuroreport* 1993; 4: 563-5.
4. TAMASHIRO LE, OLIVEIRA RD, OLIVEIRA R *et al.*: Participation of the neurotrophin brain-derived neurotrophic factor in neuropsychiatric systemic lupus erythematosus. *Rheumatology (Oxford)* 2014; 53: 2182-90.
5. HOCHBERG MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1997; 40: 1725.
6. YEE CS, FAREWELL VT, ISENBERG DA *et al.*: The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. *Rheumatology* 2011; 50: 982-8.
7. GORENSTEIN C, ANDRADE L: Inventário de depressão de Beck: propriedades psicométricas da versão em português. *Rev Psiq Clin* 1998; 25: 245-50.
8. ZHENG Q, XU MJ, CHENG J, CHEN JM, ZHENG L, LI ZG: Serum levels of brain-derived neurotrophic factor are associated with depressive symptoms in patients with systemic lupus erythematosus. *Psychoneuroendocrinology* 2017; 78: 246-52.
9. SIGNORINI V, ELEFANTE E, ZUCCHI D *et al.*: One year in review 2020: systemic lupus erythematosus. *Clin Exp Rheumatol* 2020; 38: 592-601.
10. SHARMA AN, DA COSTA E SILVA BF, SOARES JC, CARVALHO AF, QUEVEDO J: Role of trophic factors GDNF, IGF-1 and VEGF in major depressive disorder: A comprehensive review of human studies. *J Affect Disord* 2016; 197: 9-20.